Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results...
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results Of Real-World Analyses Of UZEDY; Analysis Of UZEDY Highlights High Adherence And Usage Among Patients With Treatment Barriers
梯瓦呈現了最新的精神分裂症治療研究，包括第3期SOLARIS試驗的結果，展示了接受TEV-'749（一種皮下長效注射劑）的成年患者在社交功能和生活質量方面的改善，以及對UZEDY的真實世界分析結果；UZEDY的分析凸顯了患有治療障礙的患者之間的高依從性和使用率。
- Teva's presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience
- Data show TEV-'749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date
-
Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults with schizophrenia who have barriers to treatment
- 梯瓦在2024年精神病大會上介紹了六項精神分裂症研究結果，突顯了其在神經科學領域尋找新創新的承諾。
- 數據顯示，TEV-'749藥物遞送技術至今沒有發生注射後譫妄/鎮靜綜合徵（PDSS）事件。
- 對UZEDY（利培酮）皮下長效注射劑的真實世界分析顯示，在患有治療障礙的精神分裂症成年患者中，高達理率和利用率。
TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.
以色列特拉維夫和新澤西州帕西帕尼，2024年11月01日（環球新聞社）— 梯瓦製藥，梯瓦製藥工業有限公司（紐交所和以色列證券交易所：TEVA）的美國分公司，今日宣佈了來自第3期皮下奧蘭扎丙延長釋放注射研究（SOLARIS）試驗評估精神分裂症診斷成年患者的TEV-'749社交功能和生活質量的新的積極數據。在研究的急性治療階段（第1期），TEV-'749顯示出了在從基線到第8周的社交功能和生活質量上顯著改善的成效，這是通過多項經驗證的測量確定的。TEV-'749的全身安全性與奧氮賽平（olanzapine）已批准的口服配方一致，沒有發現新的安全信號，截至目前也沒有報告PDSS事件。此外，一項評估TEV-'749的藥代動力學特性的第1期研究的體外數據和中期結果驗證了其給藥途徑和藥物遞送技術可能有效地應對PDSS發展的風險。這些突出以患者爲中心的成果的研究結果是在2024年10月29日至11月2日波士頓馬薩諸塞州舉行的2024年精神病大會上介紹的。
Schizophrenia is a complex medical condition which can severely impact quality of life and social functioning. These new results demonstrate the potential benefits TEV-'749 may have for patients utilizing this form of a long-acting injectable (LAI) treatment option including improving quality life and social functioning.1
精神分裂症是一種複雜的醫療條件，可能嚴重影響生活質量和社會功能。這些新結果展示了TEV-'749可能爲利用這種長效注射(LAI)治療選擇的患者帶來的潛在益處，包括改善生活質量和社會功能。1
譯文內容由第三人軟體翻譯。
